Lenz Therapeutics, Inc announced Vizz (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. According to a company press release, professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide.

Commercial product shipments will be initiated to consumers in October through the company's ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025, the company said. 

Vizz is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. Vizz contracts the iris sphincter muscle, resulting in a pinhole effect and achieves a sub-2 mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift.

According to the company, in the CLARITY phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses. 

“We are thrilled to introduce Vizz to the 128 million adults living with blurry near vision in the United States,” said Eef Schimmelpennink, president and chief executive officer of Lenz Therapeutics. “The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing Vizz as a Category of One for the treatment of presbyopia.”